Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations
Details
Publication Year 2024-07,Volume 25,Issue #7,Page e318-e330
Journal Title
Lancet Oncology
Publication Type
Review
Abstract
Robust time-to-event endpoint definitions are crucial for the assessment of treatment effect and the clinical value of trial interventions. Here, the Head and Neck Cancer International Group investigated endpoint use in phase 3 trials and trials considered potentially practice-changing published between 2008 and 2021 in the curative-intent setting for patients with mucosal head and neck squamous cell carcinoma. Of the 92 trials reviewed, we show that all core components of endpoint reporting were heterogeneous, including definitions of common terms, such as overall survival and progression-free survival. Our report highlights the urgent need for harmonisation of fundamental components of clinical trial endpoints and the engagement of all stakeholders to ensure the transparent reporting of endpoint details.
Publisher
Elsevier
Keywords
Humans; *Squamous Cell Carcinoma of Head and Neck/pathology/therapy/mortality; *Consensus; *Head and Neck Neoplasms/therapy/pathology/mortality; *Endpoint Determination/standards; Clinical Trials, Phase III as Topic; Progression-Free Survival
Department(s)
Medical Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-06 05:29:24
Last Modified: 2024-08-06 05:31:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙